Anti-CTLA-4 antibodies have shown potential therapeutics for gliomas [213], and combining sequential immunotherapy with GM-CSF expressing irradiated glioma cell vaccine synergistically prolongs survival in mice-bearing gliomas [214]. Here, CSF2 is linked to central nervous system cancer.